Teva Warns Fed. Circ. IP Ruling Has 'Perverse Consequences'

Teva-owned Actavis Laboratories is asking the U.S. Supreme Court to reverse a Federal Circuit written description ruling that "renounced years of established precedent" about what must be included in a patent's...

Already a subscriber? Click here to view full article